Jun Long

Dr. Jun Long

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2018 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
RQRunze Qiu
Runze Qiu
LZLiyu Zhou
Liyu Zhou
YMYuanjing Ma
Yuanjing Ma
LZLingling Zhou
Lingling Zhou
TLTao Liang
Tao Liang
DYDongping Yuan
Dongping Yuan

1 April 2021 in International Reviews of Immunology
Verified
Journal Article
Closed access
YSYuting Sun
Yuting Sun
LZLiyu Zhou
Liyu Zhou
WCWeikai Chen
Weikai Chen
LZLinhui Zhang
Linhui Zhang
HZHongbo Zeng
Hongbo Zeng
DYDongping Yuan
Dongping Yuan
An increasing number of researches have shown that cell metabolism regulates cell function. Dendritic cells (DCs), a professional antigen presenting cells, connect innate and adaptive immune responses. The preference of DCs for sugar or lipid affects its phenotypes and functions. In many diseases such as atherosclerosis (AS), diabetes mellitus and tumor, altered glucose or lipid level in microenvironment makes DCs exert ineffective or opposite immune roles, which accelerates the development of these diseases. In this article, we review the metabolism pathways of glucose and cholesterol in DCs, and the effects of metabolic changes on the phenotype and function of DCs. In addition, we discuss the effects of changes in glucose and lipid levels on DCs in the context of different diseases for better understanding the relationship between DCs and diseases. The immune metabolism of DCs may be a potential intervention link to treat metabolic-related immune diseases.

1 June 2014 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
DYDong-Ping Yuan
Dong-Ping Yuan
JLJun Long
Jun Long
YLYin Lu
Yin Lu
JLJie Lin
Jie Lin
LTLi Tong
Li Tong

1 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YYYunjun Yang
Yunjun Yang
DBDandan Bai
Dandan Bai
LJLinhong Jiang
Linhong Jiang
YCYanran Chen
Yanran Chen
MWMengyuan Wang
Mengyuan Wang
DYDongping Yuan
Dongping Yuan

31 October 2022 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
HZH. B. Zeng
H. B. Zeng
LZL. H. Zhang
L. H. Zhang
DYD. P. Yuan
D. P. Yuan
WWW. Wang
W. Wang
XSX. M. Su
X. M. Su
YSYaohong Song
Yaohong Song
As a byproduct of mitochondrial respiration or metabolism, reactive oxygen species (ROS) can act as a signaling molecule to activate NLR family pyrin domain containing 3 (NLRP3) inflammasome, thereby triggering immune response. NLRP3 inflammasome acts as a sensor of various danger signals and is central to the control of pyroptosis occurrence. Macrophage pyroptosis is closely related to atherosclerosis, arthritis, pulmonary fibrosis and other inflammatory diseases. Methylophiopogonanone A (MO-A) is a main homoisoflavonoid in Chinese herb Ophiopogonis Radix, which has antioxidant effect. However, it is not clear whether MO-A can alleviate macrophage pyroptosis by inhibiting oxidative stress. Here we have shown that MO-A increases the activities of superoxide dismutase (SOD) and catalase (CAT), inhibits the production of ROS, reduces the activation of NLRP3 inflammasome and the release of lactate dehydrogenase (LDH), and inhibits pyroptosis in macrophages induced by lipopolysaccharides (LPS) and adenosine triphosphate (ATP). These effects can be reversed by the ROS promoter H2O2. Therefore, MO-A can inhibit macrophage pyroptosis through the ROS/NLRP3 pathway and may be considered as a candidate drug for the treatment of inflammatory diseases.

20 December 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
LZLinhui Zhang
Linhui Zhang
HWHaixia Wang
Haixia Wang
ZWZishan Wang
Zishan Wang
JXJianyi Xu
Jianyi Xu
MWMengyuan Wang
Mengyuan Wang
JLJun Long
Jun Long
Cholesterol aggregation in dendritic cells (DCs) triggers an inflammatory response and accelerates the development of atherosclerosis (AS). Resveratrol (RES), a natural compound with anti-inflammatory and cholesterol metabolism regulatory properties, has been shown to influence the maturation and inflammatory functions of DCs. However, its relationship with cholesterol metabolism remains unclear. This study aimed to explore the roles of RES in cholesterol metabolism and inflammatory behaviors of DCs in the context of AS. We analyzed the effect of RES on cholesterol efflux from ApoE−/− bone marrow-derived dendritic cells (BMDCs) using qRT-PCR, Western blot, and cholesterol efflux assays; identified the inflammatory status of RES-treated BMDCs and co-cultured T cells using flow cytometry and ELISA; confirmed the effect of RES on blood lipids, atherosclerotic lesions, cholesterol metabolism, and inflammatory response in high-fat diet and lipopolysaccharide-treated ApoE−/− mice; and explored the potential targets of RES in regulating inflammatory behavior via molecular docking. The results revealed that RES promotes cholesterol efflux, increases the expression of efflux transporter ABCA1, and decreases liver X receptor alpha (LXRα) expression in response to a decrease in intracellular cholesterol in ApoE−/− BMDCs. RES also reduced MHC-II+ cells and downregulated costimulatory molecule CD80 in BMDCs with decreased IL-6 and increased IL-2 production, and suppressed T-cell activation and modulates IL-22 and IL-10 secretion via BMDCs. Furthermore, we confirmed that RES relieves arterial lesions and regulates blood lipids in ApoE−/− mice. RES demonstrated ABCA1 upregulation and LXRα downregulation effects in the aorta and regulated costimulation molecules and Th17/Treg cytokines in the spleen. Furthermore, RES showed multiple hydrogen bonding and low binding energy with ABCA1, suggesting that ABCA1 is a potential target of RES to modulate the inflammatory properties of BMDCs. Our study demonstrated that RES regulates cholesterol efflux and inflammatory behavior in BMDCs, contributing to the control of AS progression and offering new insights for managing inflammatory diseases.